drugset / Trial / NCT06121830
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is designed to determine the efficacy and safety of DWP14012 compared to a placebo following a once-daily oral dose of DWP14012 at 20 mg, 40 mg, or placebo for 4 weeks in patients with NERD.
Timeline
- Start
- 2023-08-31
- Primary completion
- 2025-01
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABEPRAZAN | Small molecule | 20 mg | Oral |
| Subject | ABEPRAZAN | Small molecule | 40 mg | Oral |